FY22 Results Presentation

Strong growth in revenue and earnings A$m Revenue FY22 FY22 FY21 Growth Prospectus Vs Prospectus 1,330.7 1,016.4 31% 1,333.2 0% Pro forma EBITDA¹ 308.0 234.7 31% 294.9 4% Pro forma EBIT2 185.6 131.5 41% 174.0 7% Pro forma profit before tax (PBT) 146.8 97.7 50% 137.9 6% Pro forma profit after tax (NPAT) 114.6 77.8 47% 103.2 11% Pro forma NPAT before amortisation (NPATA)³ 166.3 128.6 29% 155.1 7% Statutory NPATA 92.4 48.9 89% 68.2 35% 16 |FY22 Results Presentation (2) EBIT earnings before interest and tax Revenue up 31% to $1,330.7m Revenue growth split between 57% organic and 43% M&A Underpinned by strong performance in Australia, ramp-up in Restart Scheme in the UK and new acquisitions Partially offset by COVID-19 impact in APAC business and Allied Health in Australia and lower pass-through revenue Pro forma EBITDA up 31% to $308.0m Maturation of the Restart Scheme drove scale benefits partially offset by a lower second half in Australia as a result of COVID-19 absenteeism, transition to Workforce Australia and investment in integration and corporate services supporting growth Pro forma NPATA up 29% to $166.3m Effective tax rate of 22% marginally lower than prospectus driven by utilization of tax losses in the UK Estimated future pre-tax annual interest savings of $15m on margin driven by lower cost refinance in July 2022 (1) EBITDA earnings before interest, tax, depreciation and amortisation (3) Refer slide 27 for a reconciliation of pro forma EBITDA to statutory EBITDA and pro forma NPATA to statutory NPATA APM enabling better lives

View entire presentation